Literature DB >> 13677614

Syndecan-1/CD138 expression in normal myeloid, acute lymphoblastic and myeloblastic leukemia cells.

Aysel Seftalioglu1, Sema Karakus.   

Abstract

Stabilization of cell surface antigens and preservation of ultrastructural integrity are important aspects of immunoelectron microscopical studies. In the present study, 4 anti-syndecan-1/CD138 (B-B2, B-B4, MI15, 1D4) monoclonal antibodies (mAbs) were applied in combination with periodatelysine-paraformaldehyde (PLP) fixation and indirect pre-embedding peroxidase electron microscopical immunocytochemistry to analyse the localization and function of these molecules in normal myeloid cells, acute lymphoblastic leukemia (ALL) cells and acute myeloblastic leukemia (AML) cells. One case of normal human bone marrow, 3 cases of untreated AML and 2 cases of untreated ALL were studied. Samples were immediately fixed for 4 h in freshly-prepared PLP fixative in 0.037 mol/L phosphate buffer, pH 7.4, containing 10 mmol/L sodium metaperiodate, 75 mmol/L lysine, and 2% paraformaldehyde. Expression of syndecan-1 was found at the plasma membrane of all cell types. Staining intensity at the membrane of AML cells was stronger than that on the membrane of normal myeloid and ALL cells. We conclude that anti-syndecan-1/CD138 mAbs in combination with the method described here are a suitable tool for detection of cell surface syndecan molecules in cells originating from progenitor cells that can differentiate in both myeloid and lymphoid cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13677614     DOI: 10.1078/0065-1281-00706

Source DB:  PubMed          Journal:  Acta Histochem        ISSN: 0065-1281            Impact factor:   2.479


  5 in total

1.  A role for syndecan-1 and claudin-2 in microbial translocation during HIV-1 infection.

Authors:  Anthony J Smith; Timothy W Schacker; Cavan S Reilly; Ashley T Haase
Journal:  J Acquir Immune Defic Syndr       Date:  2010-11       Impact factor: 3.731

2.  MIST1-a novel marker of plasmacytic differentiation.

Authors:  Cecilia C S Yeung; Jason C Mills; Anjum Hassan; Frederike H Kreisel; TuDung T Nguyen; John L Frater
Journal:  Appl Immunohistochem Mol Morphol       Date:  2012-12

Review 3.  Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine.

Authors:  Mohamed R Akl; Poonam Nagpal; Nehad M Ayoub; Sathyen A Prabhu; Matthew Gliksman; Betty Tai; Ahmet Hatipoglu; Andre Goy; K Stephen Suh
Journal:  Oncotarget       Date:  2015-10-06

4.  Clinicopathological and prognostic significance of SDC1 overexpression in breast cancer.

Authors:  Xiangrong Cui; Xuan Jing; Qin Yi; Chunlan Long; Jie Tian; Jing Zhu
Journal:  Oncotarget       Date:  2017-11-30

5.  A stem cell reporter based platform to identify and target drug resistant stem cells in myeloid leukemia.

Authors:  Kyle Spinler; Jeevisha Bajaj; Takahiro Ito; Bryan Zimdahl; Michael Hamilton; Armin Ahmadi; Claire S Koechlein; Nikki Lytle; Hyog Young Kwon; Ferdous Anower-E-Khuda; Hao Sun; Allen Blevins; Joi Weeks; Marcie Kritzik; Jan Karlseder; Mark H Ginsberg; Pyong Woo Park; Jeffrey D Esko; Tannishtha Reya
Journal:  Nat Commun       Date:  2020-11-26       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.